Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allovir Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALVR
Nasdaq
8731
https://www.allovir.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allovir Inc
AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients
- Jun 7th, 2022 4:07 pm
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
- Jun 7th, 2022 12:30 pm
AlloVir Reports First Quarter 2022 Financial Results
- May 5th, 2022 11:00 am
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
- Apr 21st, 2022 3:35 pm
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
- Apr 20th, 2022 11:00 am
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
- Apr 4th, 2022 11:40 pm
AlloVir Appoints Shawn Tomasello to Its Board of Directors
- Mar 31st, 2022 11:00 am
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections
- Mar 23rd, 2022 1:56 pm
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
- Mar 22nd, 2022 11:00 am
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
- Feb 11th, 2022 12:00 pm
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
- Feb 10th, 2022 12:00 pm
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
- Jan 5th, 2022 12:30 pm
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2022 9:05 pm
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
- Dec 16th, 2021 9:05 pm
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
- Dec 11th, 2021 6:00 pm
Allovir Insider Sold Over $465K In Company Stock
- Nov 17th, 2021 4:57 pm
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
- Nov 15th, 2021 12:00 pm
Allovir Insider Trades $300K In Company Stock
- Nov 10th, 2021 4:48 pm
AlloVir Reports Third Quarter 2021 Financial Results
- Nov 5th, 2021 11:00 am
Morgan Stanley: These 2 ‘Strong Buy’ Stocks Could Double From Here
- Oct 29th, 2021 1:47 pm
Scroll